Membrane Transporters and Active Transport

The Na⁺/K⁺-ATPase is the direct pharmacological target of cardiac glycosides (digoxin, ouabain), historically derived from foxglove (Digitalis) and still used to treat heart failure and atrial fibrillation. By partially inhibiting the pump, these drugs raise intracellular Na⁺, which (via reduced driving force for the Na⁺/Ca²⁺ exchanger, NCX) raises intracellular Ca²⁺ in cardiac myocytes, increasing contractile force — a direct pharmacological exploitation of the coupled-transporter energetics derived above. The narrow therapeutic window of digoxin is a direct consequence of how close the pump and NCX operate to their thermodynamic margins, as the worked example on NCX made explicit.

SGLT2 inhibitors ("gliflozins": canagliflozin, dapagliflozin, empagliflozin) are now front-line drugs for type 2 diabetes and heart failure, working by blocking the renal Na⁺/glucose cotransporter SGLT2 in the proximal tubule, forcing glucose excretion in urine and lowering blood glucose — a direct pharmaceutical intervention on a secondary active transporter whose stoichiometry (1 Na⁺:1 glucose for SGLT2, versus 2 Na⁺:1 glucose for SGLT1) sets its lower-affinity, higher-capacity character. The P-type ATPase superfamily extends far beyond Na⁺/K⁺: the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA), which refills intracellular Ca²⁺ stores after muscle contraction and neuronal signaling, uses essentially the same Albers–Post-type mechanism and is the target of the plant toxin thapsigargin (a standard laboratory tool for depleting ER Ca²⁺ stores) and of investigational drugs for heart failure aiming to enhance SERCA activity and improve cardiac relaxation. Proton pumps of the same broad structural family (H⁺/K⁺-ATPase) are the direct target of proton pump inhibitors (omeprazole and related drugs), which covalently modify the pump to suppress gastric acid secretion — one of the best-selling drug classes in medicine. At the instrumentation level, patch-clamp electrophysiology directly measures the small electrogenic currents generated by Na⁺/K⁺-ATPase and NCX, distinguishing pump-mediated currents from channel currents by their characteristic voltage-dependence and sensitivity to specific blockers; this same toolkit underlies research connecting membrane transporters to Ion Channels and Selective Permeability and to the ionic basis of Signal Transduction at the Membrane, where transporter-set gradients establish the resting potential from which every action potential and receptor-triggered depolarization departs.

Ask the tutor: How does the Na⁺/K⁺-ATPase's E1-to-E2 conformational switch actually change the ion-binding site's affinity from high (for Na⁺) to low (releasing Na⁺, binding K⁺) at the molecular/structural level?

Every transporter is a conformational machine, not a static pore. Unlike a channel, which forms a continuous water-filled path across the membrane and lets ions flow anytime it's open, a transporter never presents an open path all the way through. Instead, a transporter alternates between at least two major conformations — commonly labeled outward-open and inward-open — such that a bound solute is exposed to only one side of the membrane at a time. This "alternating access" principle is the structural mechanism that prevents an active transporter from simply becoming a leak: the substrate-binding site closes off from one side before it opens to the other. For primary active transport, exemplified by the Na⁺/K⁺-ATPase, the energy for switching between conformations comes from phosphorylation and dephosphorylation of an aspartate residue in the pump, using the γ-phosphate of ATP. Phosphorylation and its hydrolysis are thermodynamically irreversible steps built into the cycle; they are what break the symmetry that would otherwise let ions leak back down their gradients through the same protein. The pump therefore has a built-in ratchet: at every point in the cycle, at least one step is essentially unidirectional at physiological concentrations. For secondary active transport, no chemical bond is broken directly by the transporter. Instead, the "downhill" flow of one solute (almost always Na⁺, sometimes H⁺) through the same protein is mechanically/conformationally coupled to the "uphill" movement of a second solute. If the coupled species move in the same direction, the transporter is a symporter (e.g., SGLT1, Na⁺/glucose); if they move in opposite directions, it's an antiporter (e.g., NCX, Na⁺/Ca²⁺ exchanger; NHE, Na⁺/H⁺ exchanger). The alternating-access conformational change is triggered only when both substrates (or neither) are bound, which is exactly what enforces the fixed stoichiometry and prevents uncoupled slip. The thermodynamic currency for all of this is the electrochemical potential, which for an ion of charge $z$ combines a chemical (concentration) term and an electrical term. Moving a mole of ions from outside to inside changes free energy by an amount that depends on the concentration ratio and the membrane potential; when this quantity is positive for "uphill" movement, an external energy source must supply at least that much free energy, with the transporter enforcing near-stoichiometric coupling so that the process runs forward and not in reverse.

The fundamental quantity governing every transport process, passive or active, is the electrochemical potential difference for solute $S$ across a membrane:

where:

• $R$ = gas constant (8.314 J mol⁻¹ K⁻¹), $T$ = absolute temperature (K)
• $C_{in}, C_{out}$ = solute concentrations inside and outside the cell
• $z$ = charge of the ion (dimensionless, signed)
• $F$ = Faraday's constant (96,485 C mol⁻¹)
• $\Delta\psi = \psi_{in} - \psi_{out}$ = membrane potential (V), typically −60 to −70 mV at rest for animal cells

Reading: $\Delta\tilde\mu_S$ is the free energy change (J/mol) for moving one mole of $S$ from outside to inside. If $\Delta\tilde\mu_S < 0$, inward movement is spontaneous (downhill); if $>0$, inward movement requires energy input (active transport). The equation is symmetric: multiplying by −1 gives the energy for outward movement. For a pump that hydrolyzes ATP to move ions, the relevant comparison is between the free energy of ATP hydrolysis and the total electrochemical work done on all transported species:

where:

• $\Delta G_{ATP} = \Delta G^{\circ\prime}_{ATP} + RT\ln\left(\dfrac{[\text{ADP}][\text{P}_i]}{[\text{ATP}]}\right)$, the actual (non-standard) free energy of ATP hydrolysis, a large negative number under cellular conditions (typically −50 to −60 kJ/mol)
• $n_i$ = stoichiometric number of ions of type $i$ moved per ATP hydrolyzed (sign convention: positive if pumped in the "uphill"/net-consuming direction)
• The sum runs over all coupled ionic species (for Na⁺/K⁺-ATPase: Na⁺ out and K⁺ in)

Reading: the pump can run forward (hydrolyzing ATP, pumping ions) only while the total uphill electrochemical cost is less in magnitude than the free energy released by ATP hydrolysis. As ion gradients build up, $\sum n_i \Delta\tilde\mu_i$ grows until it exactly balances $-\Delta G_{ATP}$; at that point the pump stalls (zero net flux), defining the maximum gradient the pump can sustain. For secondary active transport, no ATP appears; instead the driving ion's downhill flow supplies the energy:

where:

• $n_{driver}$ = moles of driving ion (e.g., Na⁺) moving down its gradient per mole of cargo transported
• $\Delta\tilde\mu_{driver}$ is negative (favorable, downhill direction as written)
• $n_{cargo}\,\Delta\tilde\mu_{cargo}$ is the energetic cost of moving the cargo (e.g., glucose) uphill, which must be more than offset

Reading: this inequality is the design constraint on cotransporter stoichiometry — it tells you the minimum number of driver ions needed to achieve a given cargo concentration ratio, which is precisely what the derivations below compute.

Example 1 (foundational): Sign and magnitude of $\Delta\tilde\mu$ for resting K⁺. A typical mammalian cell has $[K^+]_{in} = 140$ mM, $[K^+]_{out} = 4$ mM, $\Delta\psi = -70$ mV, $T=310$ K. Compute $\Delta\tilde\mu_K$ for K⁺ moving inward, and state which direction is spontaneous.

Since $\Delta\tilde\mu_K > 0$ for inward movement, K⁺ movement inward is slightly uphill — meaning outward movement is spontaneous by $-2.41$ kJ/mol. This matches physical intuition: K⁺ is far more concentrated inside, so despite the negative membrane potential pulling cations in, the concentration gradient dominates and K⁺ leaks outward through resting K⁺ channels, which is exactly what sets the resting potential close to $E_K$ via the Goldman/Nernst relations used in Ion Channels and Selective Permeability. Note this is a small residual value, not zero — the resting potential is not exactly $E_K$ because of finite Na⁺ and Cl⁻ permeabilities.

Example 2 (applied): ATP cost of restoring ion gradients after a single action potential. During one action potential, a small patch of squid giant axon membrane admits roughly $4 \times 10^{-6}\ \text{mol Na}^+$ per liter of cell volume equivalent (order-of-magnitude figure from classic radiotracer flux measurements). Estimate the ATP required to pump this Na⁺ back out, given the 3 Na⁺ : 1 ATP stoichiometry.

Using $\Delta G_{ATP} \approx -54$ kJ/mol (physiological, from Example above):

This is a small fraction of a cell's total ATP turnover per action potential but recurs at every impulse; in small-diameter unmyelinated axons, where surface-to-volume ratio is large, this restoration cost dominates the axon's basal metabolic rate — a classic argument (Attwell & Laughlin, 2001) for why myelination and larger axon diameters reduce the fractional energy budget devoted to ionic recovery, since the Na⁺ influx per impulse per unit membrane area is roughly fixed by channel kinetics but the ATP cost scales with total ions moved relative to cytoplasmic volume.

Example 3 (exam/competition level): NCX antiporter — can it export Ca²⁺ against a 10,000-fold gradient using only the Na⁺ electrochemical gradient? The cardiac Na⁺/Ca²⁺ exchanger (NCX) typically transports 3 Na⁺ in for every 1 Ca²⁺ out (electrogenic antiport). Given $[Na^+]_{out}=145$ mM, $[Na^+]_{in}=12$ mM, $[Ca^{2+}]_{in} = 100$ nM (resting cytosolic), $[Ca^{2+}]_{out} = 1.0$ mM (extracellular, physiological), $\Delta\psi = -70$ mV, $T=310$ K, determine whether the 3:1 stoichiometry can sustain this ~10,000-fold gradient ($[Ca^{2+}]_{out}/[Ca^{2+}]_{in} = 1.0\times10^{-3}/1.0\times10^{-7} = 10^4$).

Step 1: write the coupled inequality. Na⁺ flows in (favorable), Ca²⁺ flows out (unfavorable, uphill); for spontaneity:

The bracket is negative of the "inward" Ca²⁺ potential because Ca²⁺ is here moving outward; equivalently, write the outward Ca²⁺ free energy directly, with $z=+2$:

(the $-2F\Delta\psi$ term appears because moving positive charge outward against a negative-inside potential costs energy; equivalently this is $-\Delta\tilde\mu_{Ca,in}$ with $z=2$.)

Step 2: compute the Na⁺ driving term (3 Na⁺ inward).

Step 3: compute the Ca²⁺ cost (1 Ca²⁺ outward).

Step 4: combine and check the sign.

Since $\Delta G_{total} < 0$, the 3 Na⁺ : 1 Ca²⁺ stoichiometry is thermodynamically sufficient to extrude Ca²⁺ against a 10,000-fold gradient — but only barely, with a margin of about 2.25 kJ/mol. This matches known physiology: NCX operates close to thermodynamic equilibrium and can actually reverse direction (importing Ca²⁺) during membrane depolarization (e.g., during the cardiac action potential plateau), when the $-2F\Delta\psi$ term shrinks or becomes less negative — a clinically important phenomenon underlying "reverse-mode NCX" calcium influx implicated in ischemia-reperfusion injury. The small margin also explains why the plasma-membrane Ca²⁺-ATPase (PMCA), a primary active transporter, is needed as a high-affinity backup for maintaining very low resting Ca²⁺, since NCX alone is a low-affinity, high-capacity, thermodynamically marginal system.

The Na⁺/K⁺-ATPase was discovered by the Danish physiologist Jens Christian Skou in 1957, while investigating ATP-splitting activity in crab nerve membranes at the University of Aarhus. Skou was originally interested in the mechanism of local anesthetics and noticed that a membrane-bound ATPase activity required both Na⁺ and K⁺ simultaneously — neither ion alone sufficed, and the requirement disappeared when ouabain (a cardiac glycoside known to inhibit active Na⁺ transport in red blood cells) was added. This was the first direct biochemical evidence linking an enzymatic ATPase activity to the physiological process of active ion transport, previously known only indirectly through flux measurements by Hodgkin, Keynes, and others on the squid giant axon. Skou's work was met with considerable skepticism for over a decade, since the notion of a single enzyme directly coupling ATP hydrolysis to vectorial ion pumping (rather than to some diffusible intermediate) was mechanistically unprecedented. It took the subsequent isolation of the enzyme, demonstration of its phosphorylated intermediate (the aspartyl-phosphate now central to the Albers–Post cycle), and eventual X-ray crystal structures (Toyoshima and colleagues, 2000s, for the related Ca²⁺-ATPase, and later the Na⁺/K⁺-ATPase itself by Nissen, Toyoshima, and coworkers around 2007–2013) to fully validate the mechanism structurally.